Literature DB >> 20350837

Human retinal pigment epithelium-induced CD4+CD25+ regulatory T cells suppress activation of intraocular effector T cells.

Shintaro Horie1, Sunao Sugita, Yuri Futagami, Yukiko Yamada, Manabu Mochizuki.   

Abstract

Murine retinal pigment epithelial (RPE) cells suppress T-cell activation by releasing soluble inhibitory factors and promote the generation of regulatory T cells in vitro. These T cells exposed to RPE supernatants (RPE-induced Treg cells) can suppress the activation of bystander effector T cells via the production of transforming growth factor-beta (TGFbeta). In the present study, we showed that human RPE-induced Treg cells are also able to acquire regulatory function when human RPE cell lines were pretreated with recombinant TGF beta 2. These RPE-induced Treg cells produced TGF beta 1 and IL-10 but not IFN gamma, and they significantly suppressed the activation of target cell lines and intraocular T-cell clones established from patients with active uveitis. Moreover, CD4(+)CD25(+) RPE-induced Treg cells expressed CTLA-4 and Foxp3 molecules, and the CD25(+) Treg cells profoundly suppressed the T-cell activation. Thus, in vitro manipulated Treg cells acquire functions that participate in the establishment of immune tolerance in the eye. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350837     DOI: 10.1016/j.clim.2010.03.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  14 in total

1.  PD-L1(hi) retinal pigment epithelium (RPE) cells elicited by inflammatory cytokines induce regulatory activity in uveitogenic T cells.

Authors:  Yan Ke; Deming Sun; Guomin Jiang; Henry J Kaplan; Hui Shao
Journal:  J Leukoc Biol       Date:  2010-08-25       Impact factor: 4.962

2.  Tregs in Autoimmune Uveitis.

Authors:  Zhaohao Huang; Wenli Li; Wenru Su
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  The new paradigm: retinal pigment epithelium cells generated from embryonic or induced pluripotent stem cells.

Authors:  Kapil Bharti; Sheldon S Miller; Heinz Arnheiter
Journal:  Pigment Cell Melanoma Res       Date:  2010-10-07       Impact factor: 4.693

Review 4.  The immunological challenges of cell transplantation for the treatment of Parkinson's disease.

Authors:  Amanda L Piquet; Kala Venkiteswaran; Neena I Marupudi; Matthew Berk; Thyagarajan Subramanian
Journal:  Brain Res Bull       Date:  2012-04-11       Impact factor: 4.077

Review 5.  Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation.

Authors:  Manuel U Ramirez; Elizabeth R Stirling; Nancy J Emenaker; David D Roberts; David R Soto-Pantoja
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

6.  The association between neovascular age-related macular degeneration and regulatory T cells in peripheral blood.

Authors:  Christopher Fugl Madelung; Mads Krüger Falk; Torben Lykke Sørensen
Journal:  Clin Ophthalmol       Date:  2015-06-25

7.  CD200R signaling inhibits pro-angiogenic gene expression by macrophages and suppresses choroidal neovascularization.

Authors:  Shintaro Horie; Scott J Robbie; Jian Liu; Wei-Kang Wu; Robin R Ali; James W Bainbridge; Lindsay B Nicholson; Manabu Mochizuki; Andrew D Dick; David A Copland
Journal:  Sci Rep       Date:  2013-10-30       Impact factor: 4.379

Review 8.  Parainflammation, chronic inflammation, and age-related macular degeneration.

Authors:  Mei Chen; Heping Xu
Journal:  J Leukoc Biol       Date:  2015-08-20       Impact factor: 4.962

Review 9.  Targeting the complement system for the management of retinal inflammatory and degenerative diseases.

Authors:  Heping Xu; Mei Chen
Journal:  Eur J Pharmacol       Date:  2016-03-03       Impact factor: 4.432

Review 10.  Immune regulation in the aging retina.

Authors:  Mei Chen; Chang Luo; Jiawu Zhao; Gayathri Devarajan; Heping Xu
Journal:  Prog Retin Eye Res       Date:  2018-10-20       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.